Skip to content
Adrienne Monson – Lifestyle
Author:
Apotex Inc.
Apotex Completes Previously Announced Strategic Transaction with Cumberland Pharmaceuticals
July 1, 2026
Apotex first to receive Health Canada approval for SEVMIA™, a generic semaglutide for chronic weight management
June 30, 2026
Apotex expands ophthalmic portfolio with Health Canada approval of IHEEZO™
May 26, 2026
Apotex launches Apo‑Semaglutide Injection™, a generic equivalent of Ozempic®, in Canada
May 14, 2026
Apotex becomes the first Canadian‑based pharmaceutical company to receive Health Canada approval for a generic equivalent of Ozempic®
May 1, 2026
Apotex Announces FDA Approval of Generic Infuvite® Pediatric Injection, Eligible for 180‑day CGT Exclusivity (Single‑Dose Vial), Complementing its Recent Approval of Generic Infuvite Adult Injection
April 27, 2026
Apotex Announces Strategic Transaction with Cumberland Pharmaceuticals to Integrate their U.S. Branded Businesses
April 23, 2026
Apotex Announces Strategic U.S. Sterile Filling Partnership with Halo Pharmaceuticals
April 14, 2026
Apotex Announces FDA Approval of First Generic Infuvite® Adult Injection (Single Dose Vial and Pharmacy Bulk package) with 180‑Day CGT Exclusivity for the Pharmacy bulk package in Partnership with Orbicular and Gland Pharma
April 14, 2026
Apotex Receives First U.S. FDA Tentative Approval for a Generic Version of Ozempic® (Semaglutide Injection) in Partnership with Orbicular
April 10, 2026
1
2
Next Page
→